Semaglutide's mode of action: how it changes the way your body handles hunger

Step 1, binding the GLP-1 receptor

After you eat, your gut releases glucagon-like peptide-1 (GLP-1), a hormone that travels to the pancreas, the stomach, and the brain. Its job is to tell those organs that food has arrived. The problem is that GLP-1 is broken down within minutes, so its window of influence is short.

Semaglutide is a modified version of GLP-1 that resists that breakdown. Once injected, it circulates for roughly a week, binding continuously to GLP-1 receptors in the same places the natural hormone would reach, but for far longer. That sustained receptor activity is what produces the effects described below.

This is the core of the mechanism behind semaglutide in weight management: not a stimulant, not a fat-blocker, but a hormone mimic that works with the body's own signalling architecture. The NHS medicines resource on semaglutide describes this receptor pathway in patient-accessible terms.

Step 2, slowing the stomach and changing the fullness signal

One of the most practically noticeable effects of semaglutide is gastric slowing. Food moves from the stomach into the small intestine more gradually than usual. The result is that a smaller portion produces a feeling of fullness that would previously have needed a larger one, and that feeling persists for longer after the meal ends.

Separately, and independently, semaglutide acts on the hypothalamus and other appetite-regulating regions of the brain. Receptors there respond to circulating GLP-1, reducing hunger signals. Most people on Wegovy describe this as food becoming less of a preoccupation, the pull towards eating simply quietens. This is not willpower; it is a measurable change in the hormone environment the brain is working in.

The gastric and central effects compound each other. You feel full sooner, stay full longer, and want food less between meals. Together, those three changes tend to create a consistent calorie reduction without the white-knuckle effort of deliberate restriction.

Step 3 (onset, titration, and what to expect over time

Semaglutide for weight management (Wegovy) is introduced gradually, starting at 0.25 mg once weekly, then stepping up through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose) each increase separated by approximately four weeks. For more on how the effects develop across those early weeks, this page on semaglutide's onset covers the timeline in detail.

The titration schedule exists for a practical reason: the GI side effects (nausea is the most commonly reported) are directly related to the speed at which gastric emptying slows. Starting low lets the body adjust. By the time someone reaches the maintenance dose, many of those early symptoms have settled considerably.

In the STEP 1 clinical trial, published in the New England Journal of Medicine, 68 weeks of semaglutide 2.4 mg alongside lifestyle changes produced an average body-weight reduction of around 15%, a figure the study investigators attributed directly to the sustained appetite and gastric effects described above.

If you keep your pen in the fridge door at home, check the patient information leaflet for the room-temperature window that applies once you remove it for injection, the exact limits are dose- and storage-condition specific. More detail on living with semaglutide is covered on the semaglutide overview page.

How the mode of action shapes who this medicine suits

Understanding the way Wegovy works also helps explain the eligibility criteria the prescriber applies. Semaglutide does not target fat tissue directly; it reduces energy intake by changing hunger and satiety. That means it works best alongside a reduced-calorie diet and increased physical activity, both are part of the licensed indication.

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK guidance. Because it slows gastric emptying, certain pre-existing gastrointestinal conditions require careful prescriber assessment before treatment starts.

The method of action also explains why Ozempic (another semaglutide product) is not the same as Wegovy for this purpose. Ozempic is licensed for type 2 diabetes, not weight management, and the licensed dose is different. They share a mechanism but not an indication. If you are considering treatment, the starting point is a conversation about which option fits your clinical picture. You can start a free consultation with one of our prescribers to explore what is right for you.

For a broader look at how costs factor into treatment decisions, the Wegovy pricing page sets out what private treatment typically involves, including what a transparent price should cover.